Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00650494 · ClinicalTrials.gov registry record · Phase 1

Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg

A Phase 1 study of Healthy, sponsored by Mylan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
1
Study location

NCT00650494: Completed Phase 1 study of Healthy, sponsored by Mylan Pharmaceuticals.

NCT00650494 is a Phase 1 study of Healthy that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 66 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00650494, a Phase 1 study of Healthy, has completed, sponsored by Mylan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to investigate the bioequivalence of Mylan's valacyclovir hydrochloride 1000 mg tablets to GSK's Valtrex® 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administration under fed conditions.

Conditions Studied

Interventions

  • DRUG Valacyclovir Hydrochloride Tablets 1000mg
  • DRUG Valtrex® 1000 mg

Study Locations (1)

West Virginia

  • Kendle International Inc. - Morgantown

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2005-08
Est. Completion 2005-08
Phase Phase 1
Mylan Pharmaceuticals

146 total trials

What the finished NCT00650494 record still lists

NCT00650494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Valacyclovir Hydrochloride Tablets 1000mg is the first listed.

NCT00650494 reports a single indexed study location in West Virginia.

Frequently Asked Questions

What is clinical trial NCT00650494 about?

NCT00650494 is a clinical study titled "Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg". The objective of this study was to investigate the bioequivalence of Mylan's valacyclovir hydrochloride 1000 mg tablets to GSK's Valtrex® 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administration under fed conditions.

What is the current status of trial NCT00650494?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2005-08. Estimated completion is 2005-08.

What conditions does trial NCT00650494 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00650494?

The interventions under investigation include: Valacyclovir Hydrochloride Tablets 1000mg (DRUG), Valtrex® 1000 mg (DRUG).

Who is sponsoring clinical trial NCT00650494?

This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00650494 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00650494's enrollment target sits among peer trials

66 342nd of 1090 higher than 740 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02584244 · 66 participants · Phase 1

    Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • NCT03067051 · 66 participants · Phase 1

    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

  • NCT03754725 · 66 participants · Phase 1

    Ferritin and Iron Burden in SAH sIRB

  • NCT03875378 · 66 participants · Phase 2

    Transdermal Estrogen in Women With Anorexia Nervosa

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00650494, the US trial registry maintained by the National Library of Medicine. NCT00650494 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.